

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Recicort 1.77 mg/ml + 17.7 mg/ml ear drops, solution for dogs and cats

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml contains:

Active substances:

Triamcinolone acetonide 1.77 mg

Salicylic acid 17.7 mg

Excipients:

Qualitative composition of excipients and other constituents	Quantitative composition if that information is essential for proper administration of the veterinary medicinal product
Ethanol (96 per cent)	583.22 mg
Benzalkonium chloride	0.4415 mg
Purified water	

Clear colourless solution.

3. CLINICAL INFORMATION

3.1 Target species

Dogs and cats.

3.2 Indications for use for each target species

Treatment of otitis externa.

Symptomatic treatment of seborrhoeic dermatitis of the auricle.

3.3 Contraindications

Do not use in cases of hypersensitivity to corticosteroids, salicylic acid or to any of the excipients.

Do not use in animals with perforated tympanic membrane. Do not use in dogs with demodicosis.

3.4 Special warnings

For an effective treatment of otitis externa it is essential that the ear canal is meticulously cleaned and dried before first treatment to remove cerumen and/or exudate. Excess hair around the treatment area should be clipped if necessary.

For an effective treatment of seborrhoeic dermatitis existing scale and or exfoliative debris should be removed. Hair surrounding or covering the lesions may need to be clipped to enable the veterinary medicinal product to reach the affected skin.

Seborrhoeic dermatitis may be a primary disorder, but can also occur as a result of underlying disorders or disease processes (e.g. allergic disorders, endocrine disorders, neoplasia) while otitis externa is only very rarely primary and occurs mainly as a result of different underlying causes

(predisposing and perpetuating factors, neoplasia). Therefore, it is essential to identify any underlying disease process and initiate specific treatment, if considered necessary.

Furthermore, infections (bacterial, parasitic or fungal) commonly occur concurrently with seborrhoeic dermatitis or otitis externa and should be identified prior to the start of the treatment and treated specifically, if considered necessary.

3.5 Special precautions for use

Special precautions for safe use in the target species:

The maximum dose that may be administered is 7 drops per kg body weight per day. The recommended treatment dose (8-10 drops per ear; once or twice daily) should not exceed 7 drops per kg bodyweight per day. Care should be taken not to exceed this amount, particularly when treating smaller animals or when both ears require treatment. In cases of otitis externa with an infectious component (bacterial, parasitic or fungal) specific treatment should be administered if considered necessary.

Systemic corticosteroid effects are possible, especially when the veterinary medicinal product is ingested by licking.

Oral ingestion (including licking) of the veterinary medicinal product by treated animals or animals having contact with treated animals should be avoided. Additional corticosteroid treatment should be used only according to the benefit/risk assessment of the responsible veterinarian. Use with caution in animals with suspected or confirmed endocrine disorders (i.e. diabetes mellitus; hypo- or hyper-thyroidism, hyperadrenocorticism etc.). Since glucocorticosteroids are known to slow growth, use in young animals (under 7 months of age) should be based on a benefit/risk assessment by the attending veterinarian and subject to regular clinical re-evaluations.

Care should be taken to avoid contact with eyes. Do not apply the veterinary medicinal product on damaged skin. If hypersensitivity to any of the components occurs, the ear should be thoroughly washed.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

This veterinary medicinal product contains triamcinolone acetonide, salicylic acid and ethanol and may be harmful to children after accidental ingestion. Do not leave the veterinary medicinal product unattended. In case of accidental ingestion seek medical advice immediately and show the package leaflet or label to the physician.

This veterinary medicinal product may be irritating to skin or induce hypersensitivity reactions. People with known hypersensitivity to corticosteroids or salicylic acid should avoid contact with the veterinary medicinal product. Avoid skin contact with the veterinary medicinal product. Personal protective clothing consisting of single use impermeable gloves should be worn when handling the veterinary medicinal product, including rubbing in the affected skin of the animal. If contact occurs, wash hands or exposed skin and seek medical advice in case of hypersensitivity reactions or if irritation persists.

This veterinary medicinal product may be irritating to the eyes. Avoid contact with the eyes including hand-to-eye contact. If contact occurs, rinse with clean water. If eye irritation persists, seek medical advice and show the package leaflet or label to the physician.

This veterinary medicinal product may be harmful to the unborn child. As the veterinary medicinal product can be absorbed through the skin, pregnant women and women of childbearing potential should not handle this veterinary medicinal product or restrain the animal during treatment and should avoid contact with the ears of the treated animal until at least 4 hours after the application.

Treated animals should not be handled and children should not be allowed to play with treated animals until the application site is dry. It is recommended that recently treated animals should not be allowed to sleep with owners, especially children.

Special precautions for the protection of the environment:

Not applicable.

3.6 Adverse events

Dogs and cats:

Rare (1 to 10 animals / 10,000 animals treated)	Application site reddening, Application site skin scaling
Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Skin thinning ^a Adrenal suppression ^{a,b}
Undetermined frequency (cannot be estimated from the available data)	Delayed healing ^a

^a Local and systemic effects are known to be triggered with prolonged and extensive use of topical corticosteroid preparations.

^b Undetermined frequency for target species cat.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

Pregnancy and lactation:

The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Use only according to the benefit/risk assessment of the responsible veterinarian.

3.8 Interaction with other medicinal products and other forms of interaction

No data available. Use of additional corticosteroid treatment only according to the benefit/risk assessment of the responsible veterinarian.

3.9 Administration routes and dosage

Auricular use.

Ear canal

Clean the external ear canal and auricle. The recommended treatment dose is 8-10 drops instilled into the affected external ear canal(s), once or twice daily. Massage the ear and the auditory canal thoroughly yet gently to ensure proper distribution of the veterinary medicinal product.

The treatment dose (8-10 drops per ear; once or twice daily) should not exceed 7 drops per kg bodyweight per day. Care should be taken not to exceed this amount, particularly when treating smaller animals or when both ears require treatment. Treatment should be continued without interruption until a few days after complete disappearance of the clinical symptoms but no longer than 14 days. If the otitis externa does not improve after 3 days of treatment the treatment should be re-evaluated.

Auricle

For the treatment of auricular seborrhoeic dermatitis, apply twice a day a sufficient number of drops onto the auricular surface so that when spread, the affected area is covered. If necessary, rub the area gently to ensure the veterinary medicinal product reaches all the affected skin. Let dry. In severe cases the effect can be increased by applying a second and third layer immediately after the drying of the first layer provided that the total number of applied drops does not exceed the maximum dose of 7 drops per kg body weight per day. Care should be taken not to exceed this dose when treating smaller dogs and

cats.

Treatment should be continued without interruption until a few days after complete disappearance of the clinical symptoms but no longer than 14 days.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

Prolonged use of high doses of triamcinolone can induce adrenal insufficiency.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3.12 Withdrawal periods

Not applicable.

4. PHARMACOLOGICAL INFORMATION

4.1 ATCvet code: QS02BA99

4.2 Pharmacodynamics

Triamcinolone acetonide in this concentration is a moderately potent steroid. Corticosteroids have an anti-inflammatory and vasoconstrictive action. They suppress the inflammatory response and the symptoms of various disorders often associated with itching. The treatment however does not cure the underlying diseases.

Salicylic acid has an acidifying effect and also has a cerumenolytic effect through its keratolytic properties.

4.3 Pharmacokinetics

Triamcinolone acetonide can be absorbed through the skin, and, although the concentration is low, a systemic action is not excluded. After systemic absorption, triamcinolone is 60-70% bound to plasma proteins. Triamcinolone is metabolised primarily in the liver. The main metabolite is 6 β -hydroxytriamcinolone, which is excreted mainly in the form of sulfates and glucuronides in urine.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

5.2 Shelf life

Shelf-life of the veterinary medicinal product as packaged for sale: 30 months.

Shelf-life after first opening the immediate packaging: 3 months

5.3 Special precautions for storage

This veterinary medicinal product does not require any special storage conditions.

5.4 Nature and composition of immediate packaging

Carton containing a 20 ml white, low density polyethylene dropper container with high density polyethylene cap.

5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

Le Vet Beheer B.V.

7. MARKETING AUTHORISATION NUMBER(S)

VPA10475/025/001

8. DATE OF FIRST AUTHORISATION

10/03/2017

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

04/08/2025

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the [Union Product Database \(https://medicines.health.europa.eu/veterinary\)](https://medicines.health.europa.eu/veterinary).

